ArticleScientific reports2025
Migrasome-related LncRNA features predict immune microenvironment and prognosis in pancreatic cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The onset of pancreatic cancer is insidious, and the early symptoms are similar to those of common gastrointestinal diseases, which leads to easy neglect and misdiagnosis, which greatly affects the accuracy of survival prediction. Cell migration is the hallmark of malignant tumor and the key step of metastasis. Migrasome are involved in embryonic development, immune response, angiogenesis, inflammatory response, wound healing, and cancer metastasis in vivo. Considering the unknown association between migrasome and lncRNAs in pancreatic cancer, the purpose of this study was to identify migrasome-related lncRNAs (MRLs) and explore their prognostic value. In this study, we first analyzed the Pancreatic adenocarcinoma (PAAD) data in The Cancer Genome Atlas(TCGA) database and identified the correlation between MRLs and pancreatic cancer prognosis and immune infiltrating landscape. Secondly, four MRLs (MED14OS, AC141930.2, Z97832.2, LINC01091) were selected to construct a risk model as a prognostic feature. Kaplan-Meier survival analysis, Cox regression analysis, Nomogram and Time - dependent Receiver Operating Characteristic (ROC) Curve were then used to verify the accuracy of the model. And then, the Prognostic Risk Model were used in clinical to validate the accuracy. Finally, the correlation of immune score, tumor immune cell infiltration, tumor mutation load, tumor immune escape, and drug sensitivity of the risk model was systematically analyzed. The risk-prognosis model of MRLs was constructed. Survival analysis showed that the survival rate of high-risk subtypes was lower than that of low-risk subtypes. MRL features were an independent prognostic predictor, and the area under the subject working curve (AUC) for 1-year, 3-year, and 5-year were 0.667, 0.780, and 0.865, respectively. Prognosis MRLs is related to immune infiltrating landscape and can reflect the immune status, immune response, tumor mutation burden and drug sensitivity of pancreatic cancer patients. At the same time, this model can distinguish clinical patients well. The results of this study construct a predictive model of pancreatic cancer associated with migrasome, and clarify the relevance of this model to immunotherapy and so on. It provides a new idea for improving immunotherapy and drug therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.